Details for Patent: 11,077,106
✉ Email this page to a colleague
Which drugs does patent 11,077,106 protect, and when does it expire?
Patent 11,077,106 protects BALVERSA and is included in one NDA.
This patent has thirty-two patent family members in twenty-seven countries.
Summary for Patent: 11,077,106
Title: | Cancer treatment |
Abstract: | The present invention provides a method for the treatment of cancer with erdafitinib. |
Inventor(s): | Stuyckens; Kim (Heist-op-den-berg, BE), Perez Ruixo; Juan Jose (Valencia, ES), De Porre; Peter Marie Z. (Sint-Denijs-Westrem, BE), Avadhani; Anjali Narayan (Chalfont, PA), Loriot; Yohann (Villejuif, FR), Siefker-Radtke; Arlene O. (Pearland, TX) |
Assignee: | Janssen Pharmaceutica NV (Beerse, BE) |
Application Number: | 16/483,579 |
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 11,077,106
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS | ⤷ Try a Trial | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS | ⤷ Try a Trial | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,077,106
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
17209098 | Dec 20, 2017 |
PCT Information | |||
PCT Filed | February 02, 2018 | PCT Application Number: | PCT/EP2018/052694 |
PCT Publication Date: | August 09, 2018 | PCT Publication Number: | WO2018/141921 |
International Family Members for US Patent 11,077,106
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2018216969 | ⤷ Try a Trial | |||
Brazil | 112019016043 | ⤷ Try a Trial | |||
Canada | 3049737 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |